These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27612019)

  • 1. Challenges and Opportunities in Rare Disease Drug Development.
    Smith BP
    Clin Pharmacol Ther; 2016 Oct; 100(4):312-4. PubMed ID: 27612019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
    Bashaw ED
    Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs Against Rare Diseases: Are The Regulatory Standards Higher?
    Gobburu J; Pastoor D
    Clin Pharmacol Ther; 2016 Oct; 100(4):322-3. PubMed ID: 27326701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Don't Do Different Things…Do Things Differently! Drug Development in Rare Diseases.
    Rudek MA; Korth-Bradley JM
    Clin Pharmacol Ther; 2016 Oct; 100(4):333-5. PubMed ID: 27393720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orphanage at the FDA.
    Chen E
    J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
    [No Abstract]   [Full Text] [Related]  

  • 7. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 8. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.
    Copley-Merriman K
    Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343
    [No Abstract]   [Full Text] [Related]  

  • 9. Accelerating orphan drug development.
    Coté TR; Xu K; Pariser AR
    Nat Rev Drug Discov; 2010 Dec; 9(12):901-2. PubMed ID: 21119719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duel over discounts. Pharma, providers at odds over 'orphan drugs'.
    Daly R
    Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763
    [No Abstract]   [Full Text] [Related]  

  • 11. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
    Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA; Freeman SN; Imoisili MA; Coté TR
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases.
    Sachs-Barrable K; Conway J; Gershkovich P; Ibrahim F; Wasan KM
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1429-34. PubMed ID: 24512098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.
    Hong YD; Villalonga-Olives E; Perfetto EM
    Value Health; 2019 Aug; 22(8):925-930. PubMed ID: 31426934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare-disease drugs to receive consideration on par with serious-disease drugs.
    Thompson CA
    Am J Health Syst Pharm; 2012 Nov; 69(22):1936-7. PubMed ID: 23135552
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical pharmacology as a cornerstone of orphan drug development.
    Bashaw ED; Huang SM; Coté TR; Pariser AR; Garnett CE; Burckart G; Zhang L; Men AY; Le CD; Charlab R; Gobburu JV; Lesko LJ
    Nat Rev Drug Discov; 2011 Oct; 10(11):795-6. PubMed ID: 22037026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.